Blue Crest Capital Management LTD Exact Sciences Corp Transaction History

Blue Crest Capital Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $1.33 Million - $1.75 Million	23,700 New	23,700 $1.64 Million
Q1 2020 May 15, 2020	SELL	$37.9 - $104.44 $429,331 - $1.18 Million	-11,328 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $647,995 - $832,230	8,344 Added 279.62%	11,328 $1.05 Million
Q3 2019 Nov 14, 2019	BUY	$90.37 - $122.49 $269,664 - $365,510	2,984 New	2,984 $270,000
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $2.95 Million - $3.9 Million	-33,006 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$61.98 - $96.5 $2.05 Million - $3.19 Million	33,006 New	33,006 $2.86 Million
Q4 2018 Feb 14, 2019	SELL	$56.04 - $82.66 $340,499 - $502,242	-6,076 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $9.3 Million - $15.5 Million	-192,491 Reduced 96.94%	6,076 $480,000
Q2 2018 Aug 14, 2018	BUY	$37.84 - $69.96 $7.12 Million - $13.2 Million	188,283 Added 1830.83%	198,567 $11.9 Million
Q1 2018 May 15, 2018	BUY	$39.82 - $57.53 $409,508 - $591,638	10,284 New	10,284 $415,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.